human
metapneumoviru
hmpv
infect
caus
respiratori
tract
diseas
similar
observ
human
respiratori
syncyti
viru
infect
hrsv
hmpv
infect
report
across
entir
age
spectrum
although
sever
diseas
occur
young
children
vaccin
chemotherapeut
antibodi
present
avail
prevent
treat
hmpv
infect
studi
bovinehuman
chimer
parainfluenza
viru
type
bh
express
human
parainfluenza
type
fusion
f
hemagglutininneuraminidas
hn
protein
engin
express
hmpv
fusion
f
protein
second
genom
posit
bh
goal
gener
novel
hmpv
vaccin
bh
previous
shown
protect
hamster
challeng
wt
hmpv
tang
rs
schickli
jh
macphail
fernand
f
bicha
l
spaet
j
et
al
effect
human
metapneumoviru
respiratori
syncyti
viru
antigen
insert
two
proxim
genom
posit
bovinehuman
parainfluenza
viru
type
viru
replic
immunogen
j
virol
evalu
efficaci
immunogen
african
green
monkey
agm
agm
immun
intranas
intratrach
bh
gener
hmpvand
humor
cellular
immun
respons
protect
wt
hmpv
infect
separ
studi
hostrang
restrict
bh
replic
rel
wt
perform
rhesu
monkey
demonstr
attenu
studi
show
bh
immunogen
protect
attenu
nonhuman
primat
warrant
evalu
human
vaccin
candid
prevent
hmpvassoci
respiratori
tract
diseas
human
metapneumoviru
hmpv
respiratori
pathogen
first
isol
netherland
nasopharyng
aspir
taken
young
children
suffer
respiratori
tract
diseas
attribut
human
respipathogen
human
bovin
rsv
pneumoviru
mice
pvm
hmpv
newli
emerg
viru
circul
human
popul
year
sinc
also
identifi
north
south
america
well
asia
africa
australia
patient
young
year
old
year
age
hmpv
infect
occur
winter
peak
incid
northern
hemispher
decemb
februari
clinic
syndrom
associ
hmpv
infect
similar
observ
rsv
infect
rang
mild
respiratori
ill
bronchiol
pneumonia
impact
hmpv
infect
appear
greatest
infant
elderli
immunocompromis
similar
popul
atrisk
sever
rsv
infect
seven
twelv
percent
respiratori
tract
ill
young
children
attribut
hmpv
infect
although
hmpvassoci
diseas
rate
lower
young
elderli
adult
full
extent
diseas
burden
health
care
cost
associ
hmpv
infect
still
undetermin
live
attenu
hmpv
vaccin
would
appropri
addit
vaccin
current
develop
pediatr
respiratori
tract
diseas
caus
hrsv
human
parainfluenza
viru
type
two
main
genet
lineag
hmpv
identifi
b
divid
two
sublineag
group
repres
group
b
therefor
vaccin
strategi
hmpv
infect
must
effect
group
hmpv
comparison
hmpv
sequenc
europ
asia
south
america
show
geograph
cluster
antigen
drift
b
virus
hmpvinfect
ferret
hamster
sera
neutral
homolog
group
virus
better
virus
belong
heterolog
group
effect
also
observ
african
green
monkey
agm
sera
howev
hamster
agm
infect
hmpv
one
group
effect
protect
challeng
heterolog
group
hmpv
although
protect
epitop
hmpv
identifi
glycoprotein
hrsv
shown
play
major
role
induc
immun
protect
three
hmpv
surfac
glycoprotein
predict
amino
acid
sequenc
f
protein
ident
highli
conserv
genet
lineag
hmpv
sh
ident
g
ident
glycoprotein
poorli
conserv
hmpv
f
protein
thu
like
major
antigen
induc
crossprotect
hamster
agm
previous
shown
chimer
viru
express
f
protein
bh
elicit
hmpv
serum
neutral
antibodi
protect
hamster
homolog
hmpv
challeng
similar
approach
use
hpiv
vector
express
group
hmpv
f
protein
protect
hamster
group
group
b
hmpv
infect
studi
abil
bh
induc
protect
immun
hmpv
infect
evalu
nonhuman
primat
anim
close
relat
human
genet
agm
highli
permiss
hmpv
infect
provid
good
model
assess
immunogen
efficaci
bh
vaccin
candid
reason
hostrang
restrict
replic
deriv
rel
evalu
agm
howev
restrict
replic
compar
previous
demonstr
respiratori
tract
chimpanze
rhesu
monkey
attenu
phenotyp
shown
correl
safeti
profil
human
infant
previous
shown
viru
vector
restrict
replic
upper
lower
respiratori
tract
rhesu
monkey
compar
replac
bovin
f
hn
gene
human
f
hn
result
intermedi
level
attenu
compar
replic
chimer
bh
viru
wt
recombin
bovin
parainfluenza
viru
express
human
f
hn
gene
bh
respiratori
tract
rhesu
monkey
result
studi
african
green
rhesu
monkey
indic
bh
elicit
hmpvand
humor
cellular
immun
respons
efficaci
attenu
thu
evalu
vaccin
candid
human
warrant
assess
potenti
pediatr
vaccin
prevent
respiratori
tract
diseas
caus
hmpv
vero
cell
maintain
modifi
eagl
medium
mem
jrh
bioscienc
supplement
mm
lglutamin
nonessenti
amino
acid
neaa
antibiot
fb
bh
propag
vero
cell
viru
stock
prepar
infect
vero
cell
multipl
infect
moi
pfucel
bh
harvest
day
postinfect
hmpv
strain
harvest
day
postinfect
follow
incub
c
presenc
trypsin
enhanc
growth
vero
cell
omit
infect
cell
media
collect
togeth
stabil
spg
sucros
kh
po
k
hpo
lglutam
final
concentr
stabil
viru
stock
store
c
bh
bh
titer
determin
plaqu
assay
vero
cell
vero
cell
infect
serial
dilut
viru
sampl
overlaid
medium
jrh
bioscienc
contain
methylcellulos
fetal
bovin
serum
day
incub
c
overlay
remov
cell
fix
methanol
follow
methanol
fixat
bh
plaqu
immunostain
polyclon
ferret
hmpv
antiserum
medimmun
vaccin
inc
secondari
hrpconjug
goat
antiferret
igg
immunolog
consult
laboratori
usa
plaqu
immunostain
primari
polyclon
goat
antibodi
vrmd
inc
wa
usa
crossreact
antigen
secondari
rabbit
antigoat
igg
conjug
horseradish
peroxidas
dako
corpor
ca
usa
hmpv
plaqu
assay
perform
way
except
overlay
contain
optimem
invitrogen
infect
cell
incub
c
day
prior
immunostain
primari
secondari
antibodi
use
dilut
except
ferret
hmpv
antiserum
use
immunostain
african
green
monkey
cercopithecu
aethiop
year
old
weigh
kg
screen
exposur
hmpv
use
plaqu
reduct
neutral
assay
prna
hemagglutin
inhibit
hai
assay
respect
describ
prescreen
done
sera
collect
day
prior
initi
studi
hmpv
seroneg
anim
select
studi
sierra
biomed
iacuc
committe
approv
protocol
procedur
involv
use
care
monkey
accord
regul
usda
anim
welfar
act
complianc
sierra
biomed
anim
welfar
assur
file
nation
institut
health
monkey
individu
hous
biocontain
cage
gener
maintain
contain
minim
inappropri
spread
live
virus
monkey
infect
intranas
intratrach
bh
pfuml
pfuml
optimem
invitrogen
contain
sucrosephosphateglutam
mixtur
spg
placebo
day
anim
receiv
nasal
dose
volum
ml
per
nostril
tracheal
dose
volum
ml
placebo
anim
group
receiv
dose
volum
optimem
supplement
spg
prior
dose
monkey
lightli
sedat
vv
mixtur
ketamin
diazepam
mgkg
ketamin
mgkg
diazepam
day
anim
challeng
intratrach
intranas
pfu
wt
dose
volum
ml
site
nasopharyng
np
swab
collect
daili
day
postimmun
postchalleng
monkey
use
steril
cotton
swab
premoisten
optimem
contain
spg
cotton
swab
place
tube
contain
ml
optimem
spg
immedi
frozen
dri
ice
bronchoalveolar
lavag
bal
specimen
collect
altern
day
postimmun
postchalleng
bal
collect
monkey
sedat
use
ketaminevalium
mixtur
allow
passag
steril
laryngoscop
endotrach
tube
feed
tube
pass
endotrach
tube
ml
mlkg
warm
steril
salin
instil
gentli
suction
back
syring
promptli
bal
sampl
stabil
spg
two
aliquot
sampl
prepar
frozen
dri
ice
store
c
blood
sampl
obtain
femor
vein
collect
day
prior
dose
prior
challeng
challeng
serolog
analysi
sera
store
c
measur
neutral
antibodi
titer
heparin
blood
separ
collect
day
process
peripher
blood
mononuclear
cell
anim
monitor
indic
fever
measur
chang
bodi
temperatur
sign
cold
runni
nose
sneez
loss
appetit
bodi
weight
viru
present
frozen
np
bal
specimen
quantit
plaqu
assay
vero
cell
plaqu
visual
immunostain
hmpvspecif
ferret
polyclon
antibodi
medimmun
vaccin
inc
describ
rhesu
monkey
macaca
mulatta
rang
year
age
weigh
kg
screen
exposur
hmpv
describ
screen
done
sera
collect
week
prior
initi
studi
hmpv
seroneg
anim
select
studi
care
use
monkey
accord
guidelin
describ
agm
studi
rhesu
monkey
individu
hous
stainlesssteel
cage
group
anim
infect
viru
kept
separ
anim
room
minim
inappropri
spread
live
virus
rhesu
monkey
infect
intratrach
bh
wt
studi
bh
studi
b
rout
inocul
design
replic
previou
attenu
studi
perform
rhesu
monkey
tracheal
dose
volum
ml
contain
log
pfu
bh
log
pfu
log
pfu
log
pfu
bh
optimem
invitrogen
stablil
spg
monkey
lightli
sedat
prior
dose
nasopharyng
np
swab
collect
daili
day
postimmun
bronchoalveolar
lavag
bal
specimen
collect
altern
day
postimmun
light
sedat
describ
agm
studi
sampl
stabil
spg
frozen
dri
ice
store
c
blood
collect
venipunctur
peripher
vein
day
prior
dose
store
c
serolog
analysi
rhesu
monkey
also
monitor
clinic
sign
cold
viru
titrat
np
bal
specimen
perform
vero
cell
plaqu
visual
immunostain
hmpvspecif
polyclon
antibodi
enumer
primat
sera
heatinactiv
c
h
twofold
serial
dilut
incub
pfu
hmpv
presenc
guinea
pig
complement
h
c
serumviru
mixtur
transfer
vero
cell
monolay
overlaid
methylcellulos
optimem
invitrogen
antibiot
day
incub
c
monolay
immunostain
use
hmpv
ferret
polyclon
antiserum
visual
plaqu
count
neutral
titer
express
reciproc
log
highest
serum
dilut
inhibit
viral
plaqu
microneutr
assay
perform
vero
cell
serial
twofold
dilut
heatinactiv
primat
serum
start
incub
c
h
tcid
serumviru
mixtur
transfer
cell
monolay
plate
incub
c
day
well
observ
cpe
neutral
titer
express
reciproc
highest
serum
dilut
inhibit
cpe
neutral
antibodi
titer
lowest
serum
dilut
test
assign
reciproc
log
titer
hai
assay
perform
incub
serial
twofold
dilut
primat
serum
c
min
eight
ha
ml
either
subsequ
guinea
pig
red
blood
cell
ad
well
incub
continu
min
follow
incub
well
observ
hemagglutin
hai
titer
express
reciproc
highest
dilut
antiserum
inhibit
virusmedi
agglutin
erythrocyt
heparin
blood
collect
bh
placebotr
african
green
monkey
day
peripher
blood
mononuclear
cell
pbmc
separ
whole
blood
ficollhypaqu
pharmacia
densiti
gradient
centrifug
frozen
liquid
nitrogen
thaw
pbmc
resuspend
complet
medium
medium
invitrogen
mm
lglutamin
antibiot
supplement
fetal
bovin
serum
hyclon
cell
incub
h
c
co
incub
viabl
cell
count
perform
h
serial
threefold
dilut
pbmc
suspens
cellsml
prepar
complet
medium
dilut
cell
seed
duplic
well
start
ml
onto
antihuman
antibodi
coat
elispot
plate
bd
bioscienc
preseed
ml
dilut
viru
vero
cell
lysat
pfuwel
uninfect
vero
cell
lysat
virus
grown
vero
cell
describ
elispot
plate
incub
c
h
follow
incub
cell
remov
multipl
round
wash
pb
plate
develop
elispot
use
biotinconjug
antihuman
streptavidin
conjug
hors
radish
peroxidas
bd
bioscienc
sever
wash
perform
pb
contain
follow
final
pb
wash
addit
aec
chromogen
substrat
develop
spot
count
use
dissect
microscop
stimul
ngml
phorbol
myrist
acid
pma
sigma
ngml
ionomycin
sigma
cell
densiti
result
spotswel
agm
highli
permiss
hmpv
infect
result
high
viru
titer
lower
lrt
upper
respiratori
tract
urt
three
group
n
hmpvand
agm
immun
intranas
intratrach
bh
placebo
fig
shed
virus
measur
plaqu
assay
bh
detect
day
nasal
swab
fig
mean
peak
titer
log
pfuml
tabl
day
bal
mean
peak
titer
log
pfuml
wt
shed
day
nasopharynx
day
trachea
mean
peak
titer
log
pfuml
respect
tabl
fig
mean
peak
titer
nasopharynx
approxim
log
higher
hmpv
anoth
group
isol
hmpv
sign
rhinorrhea
fever
note
infect
anim
postvaccin
hmpv
challeng
data
shown
thu
bh
replic
effici
urt
lrt
agm
achiev
titer
higher
wt
efficaci
bh
evalu
follow
challeng
log
pfu
wt
four
week
postvaccin
protect
defin
reduct
least
hmpv
titer
urt
lrt
compar
placebo
group
immun
tabl
immun
african
green
monkey
bh
protect
wt
challeng
tabl
fig
none
bh
anim
detect
challeng
viru
lrt
tabl
two
anim
vaccin
bh
shed
low
level
challeng
viru
urt
peak
titer
log
pfuml
day
respect
result
mean
peak
titer
log
pfuml
tabl
contrast
mean
peak
titer
placebo
group
log
pfuml
urt
lrt
respect
fig
tabl
expect
anim
fulli
protect
tabl
fig
therefor
bh
protect
agm
effect
hmpv
infect
lrt
site
hmpvassoci
bronchiol
pneumonia
hmpv
neutral
antibodi
respons
follow
immun
bh
quantifi
use
prna
tabl
agm
infect
wt
display
log
rise
neutral
antibodi
titer
log
subgroup
b
hmpv
week
postinfect
lower
rise
hmpv
neutral
antibodi
titer
detect
sera
bh
anim
signific
tabl
group
antibodi
f
protein
neutral
viru
effici
day
sera
show
rise
hmpv
neutral
antibodi
titer
subgroup
b
hmpv
tabl
bh
group
show
small
increas
hmpv
neutral
antibodi
titer
hmpv
b
challeng
statist
signific
therefor
bh
immun
result
robust
neutral
antibodi
respons
wt
also
crossneutr
wt
abil
bh
elicit
neutral
hemagglutin
inhibit
serum
antibodi
evalu
determin
whether
vaccin
anim
could
also
protect
infect
tabl
day
sera
anim
immun
bh
exhibit
high
neutral
antibodi
titer
log
high
titer
human
hai
antibodi
log
also
detect
bh
sera
day
respect
expect
lower
hai
antibodi
titer
log
observ
day
heterolog
bovin
antigen
suggest
immun
agm
bh
would
provid
protect
antibodi
respons
infect
determin
frequenc
secret
cell
follow
immun
elispot
assay
perform
pbmc
agm
inocul
bh
wt
placebo
fig
show
number
secret
cell
per
pbmc
treatment
group
n
frequenc
secret
cell
agm
immun
bh
greater
follow
stimul
compar
uninfect
vero
cell
lysat
pbmc
agm
also
easili
detect
level
secret
cell
stimul
wt
hmpv
although
one
anim
weak
cell
respons
result
larg
error
bar
fig
placebo
anim
clear
cell
respons
follow
wt
challeng
reproduc
weaker
anim
placebo
anim
also
show
lower
rise
hmpv
neutral
antibodi
titer
wt
challeng
perhap
immun
respons
placebo
treat
anim
relat
tabl
elispot
assay
perform
day
postimmun
day
postchalleng
thu
popul
secret
cell
detect
like
repres
memori
popul
howev
interest
note
cell
respons
treatment
group
day
compar
show
wt
hmpv
challeng
serv
antigen
hai
assay
b
one
four
placebo
anim
posit
prescreen
day
posit
anim
includ
mean
increas
frequenc
secret
cell
thu
vaccin
agm
bh
elicit
hmpvand
cell
respons
restrict
growth
respiratori
tract
rhesu
monkey
phenotyp
correl
attenu
safeti
human
character
safeti
profil
bh
rhesu
monkey
immun
intratrach
bh
wt
studi
bh
studi
b
monitor
viru
shed
daili
observ
also
conduct
entir
cours
studi
day
clinic
sign
chang
food
consumpt
bodi
weight
bodi
temperatur
note
nasopharynx
bh
detect
three
four
anim
day
daili
mean
peak
titer
log
pfuml
fig
anim
shed
detect
viru
seroconvert
show
high
reciproc
hai
antibodi
titer
log
day
data
shown
low
level
bh
detect
day
contrast
high
titer
log
pfuml
wt
detect
day
fig
trachea
bh
replic
peak
day
fig
mean
peak
titer
log
pfuml
fig
anim
shed
detect
viru
urt
also
detect
viru
lrt
fig
wt
anim
support
high
level
viral
replic
mean
peak
titer
log
higher
deriv
fig
thu
deriv
replic
lower
level
respiratori
tract
rhesu
monkey
compar
wt
differ
titer
log
could
readili
measur
urt
rhesu
monkey
differ
log
report
lrt
demonstr
substanti
variabl
attenu
model
howev
differ
titer
report
compar
studi
two
side
wilcoxon
exact
pvalu
show
signific
differ
urt
lrt
titer
bh
wt
group
p
howev
titer
bh
bh
urt
lrt
significantli
differ
p
therefor
bh
replic
level
viru
attenu
safe
human
infant
hmpv
infect
young
infant
signific
medic
problem
although
incid
hmpv
infect
appear
less
common
hrsv
compar
vaccin
antivir
current
avail
prevent
treat
respiratori
diseas
caus
hmpv
infect
tissu
culturebas
assay
ribavirin
ivig
prepar
contain
high
titer
hmpvneutral
antibodi
log
ml
found
inhibit
hmpv
replic
util
reagent
treatment
hmpv
infect
human
remain
test
strategi
present
util
attenu
viru
vector
deliv
hmpv
f
protein
aim
induc
humor
cellmedi
immun
hmpv
infect
vector
approach
previous
shown
gener
promis
hrsv
vaccin
candid
well
respiratori
pathogen
measl
viru
sar
coronaviru
two
main
genet
lineag
hmpv
identifi
immun
strategi
must
address
question
crossprotect
two
major
group
hmpv
result
anim
studi
suggest
infect
one
group
hmpv
provid
crossprotect
infect
hmpv
subgroup
hmpv
f
protein
highli
conserv
among
differ
lineag
hmpv
suffici
provid
protect
anim
hmpv
infect
absenc
hmpv
surfac
glycoprotein
g
sh
furthermor
exposur
hmpv
f
protein
group
hmpv
protect
anim
infect
group
b
hmpv
present
studi
challeng
bh
anim
subgroup
b
hmpv
howev
sera
bh
agm
show
rise
neutral
titer
seen
level
crossneutr
also
seen
previou
anim
studi
wt
hamster
agm
despit
lower
titer
crossneutr
antibodi
heterolog
group
hmpv
effect
protect
heterolog
group
hmpv
challeng
observ
hamster
agm
studi
bh
shown
elicit
hmpvspecif
well
virusspecif
antibodi
cell
respons
agm
receiv
vaccin
viru
hmpvspecif
cell
respons
lower
agm
immun
bh
compar
anim
like
one
hmpv
antigen
express
chimer
viru
cellular
immun
respons
demonstr
human
rsv
infect
thought
contribut
clear
rsv
infect
mice
like
cellmedi
immun
also
contribut
effect
protect
crossprotect
differ
hmpv
strain
although
sera
agm
infect
bh
express
group
hmpv
f
glycoprotein
show
lower
neutral
titer
group
b
presenc
humor
cellular
immun
respons
suggest
vaccin
agm
may
also
protect
group
b
hmpv
infect
question
consider
interest
use
viru
vector
deliveri
antigen
whether
host
develop
immun
vector
import
use
vector
deliv
differ
antigen
sequenti
vaccin
also
fulfil
need
boost
event
primari
vaccin
insuffici
induc
last
protect
immun
second
point
particularli
relev
target
popul
young
infant
undevelop
immun
system
may
need
multipl
dose
stimul
robust
protect
respons
clear
long
immun
respons
hmpv
andor
persist
agm
report
humor
immun
last
month
hamster
unabl
detect
decay
hai
antibodi
titer
hmpv
neutral
antibodi
titer
hamster
month
immun
pfu
pfu
bh
data
shown
appar
longterm
immun
seen
hamster
may
reflect
immun
statu
infect
young
infant
recent
clinic
trial
young
infant
show
multipl
dose
attenu
result
inhibitori
vector
immun
provid
interv
dose
administr
time
appropri
infant
shed
viru
second
dose
vaccin
administ
month
later
contrast
infant
shed
viru
second
dose
interv
primari
secondari
dose
month
thu
boost
regimen
maxim
vaccin
take
durat
immun
young
infant
month
month
maternallyderiv
hai
serum
antibodi
titer
high
log
weekold
infant
appear
interfer
replic
attenu
vaccin
strain
sinc
shown
suffici
efficaci
immunogen
attenu
bh
primat
model
might
interest
test
effect
boost
abil
bh
effect
protect
urt
agm
hmpv
challeng
safeti
profil
bh
evalu
rhesu
monkey
high
permiss
agm
bh
preclud
use
primat
model
evalu
host
rang
restrict
replic
rel
wt
rhesu
monkey
show
clinic
sign
infect
howev
clinic
sign
report
agm
infect
wt
wt
hmpv
infect
lack
clinic
sign
observ
agm
infect
bh
addit
indic
chimer
vaccin
viru
attenu
attenu
phenotyp
human
resid
multipl
gene
f
hn
gene
contain
genet
determin
specifi
attenu
major
contributor
attenu
phenotyp
ascrib
n
p
protein
polygen
distribut
attenu
marker
predict
attenu
phenotyp
stabl
inde
shown
isol
seroneg
children
phenotyp
stabl
retain
hostrang
restrict
replic
rhesu
monkey
stabil
insert
hmpv
f
test
vivo
howev
bh
ident
vector
express
rsv
f
gene
second
genom
posit
found
retain
rsv
f
express
four
serial
passag
respiratori
tract
hamster
nonetheless
stabl
retent
ad
hmpv
f
gene
need
evalu
human
main
goal
studi
evalu
bh
potenti
hmpv
vaccin
also
determin
level
serum
hai
neutral
antibodi
titer
follow
vaccin
even
though
direct
challeng
perform
studi
magnitud
rise
hai
neutral
antibodi
primat
sera
anim
immun
bh
correl
antibodi
level
give
protect
lrt
infect
rhesu
monkey
infant
also
abl
detect
virusspecif
tcell
respons
agm
immun
bh
presenc
virusspecif
humor
tcell
respons
suggest
bh
vector
hmpv
vaccin
might
function
bival
vaccin
immun
hmpv
infect
final
hmpv
vaccin
bh
like
coadminist
vaccin
respiratori
syncyti
viru
rsv
formul
consist
bh
bh
also
shown
attenu
protect
bh
formul
attenu
live
rsv
provid
protect
hmpv
well
rsv
infant
formul
interfer
vaccin
virus
need
evalu
altern
bh
could
engin
express
rsv
hmpv
f
howev
concern
genet
stabil
bh
express
three
heterolog
f
protein
thoroughli
address
preclin
studi
need
identifi
efficaci
safe
stabl
trival
vaccin
prevent
rsv
hmpv
infect
infant
